TOFACITINIB CITRATE - Generic Drug Details

What are the generic sources for tofacitinib citrate and what is the scope of patent protection?

Tofacitinib citrate is the generic ingredient in three branded drugs marketed by Hikma, Pfizer, Ajanta Pharma Ltd, Aurobindo Pharma Ltd, Biocon Pharma, Dexcel, Sinotherapeutics Inc, Zydus Pharms, Micro Labs, and Pf Prism Cv, and is included in thirteen NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Tofacitinib citrate has one hundred and twenty-four patent family members in fifty-five countries.

There are twelve drug master file entries for tofacitinib citrate. Two suppliers are listed for this compound. There are seven tentative approvals for this compound.

Summary for TOFACITINIB CITRATE

International Patents:	124
US Patents:	4
Tradenames:	3
Applicants:	10
NDAs:	13
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	12
Patent Applications:	1,792
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TOFACITINIB CITRATE
DailyMed Link:	TOFACITINIB CITRATE at DailyMed

Recent Clinical Trials for TOFACITINIB CITRATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Army Medical University, China	PHASE4
Jinnah Hospital	PHASE3
China-Japan Friendship Hospital	Phase 4

See all TOFACITINIB CITRATE clinical trials

Generic filers with tentative approvals for TOFACITINIB CITRATE

Applicant	Application No.	Strength	Dosage Form
		EQ 5MG BASE	TABLET;ORAL
		EQ 11MG BASE	TABLET, EXTENDED RELEASE;ORAL
		10MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for TOFACITINIB CITRATE

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for TOFACITINIB CITRATE

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

L04AF	Janus-associated kinase (JAK) inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for TOFACITINIB CITRATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XELJANZ	Oral Solution	tofacitinib citrate	1 mg/mL	213082	1	2021-11-12
XELJANZ XR	Extended-release Tablets	tofacitinib citrate	22 mg	208246	1	2020-12-28
XELJANZ	Tablets	tofacitinib citrate	10 mg	203214	1	2019-07-24
XELJANZ	Tablets	tofacitinib citrate	5 mg	203214	3	2016-11-07
XELJANZ XR	Extended-release Tablets	tofacitinib citrate	11 mg	208246	1	2016-11-07

US Patents and Regulatory Information for TOFACITINIB CITRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No	RE41783*PED				Y
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012		RX	Yes	No
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012		RX	Yes	No
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018		RX	Yes	Yes	RE41783*PED				Y
Zydus Pharms	TOFACITINIB CITRATE	tofacitinib citrate	TABLET;ORAL	209829-001	Mar 13, 2023		DISCN	No	No

Expired US Patents for TOFACITINIB CITRATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012	7,091,208
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	6,965,027
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020	7,301,023
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020	6,956,041
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	6,956,027

International Patents for TOFACITINIB CITRATE

Country	Patent Number	Title	Estimated Expiration
Mexico	382075	FORMA DE DOSIS ORALES DE LIBERACIÓN SOSTENIDA DE TOFACITINIB. (TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS)
Japan	6314188
World Intellectual Property Organization (WIPO)	2014147526
Germany	60037345
Norway	323378

Supplementary Protection Certificates for TOFACITINIB CITRATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1666481	17C1031	France		PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324
1666481	132017000095300	Italy		PRODUCT NAME: TOFACITINIB, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE, COMPRENDENTE IL SALE CITRATO(XELJANZ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1178/001-004, 20170324
1666481	122017000062	Germany		PRODUCT NAME: TOFACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1178 20170322
1235830	C01235830/01	Switzerland		PRODUCT NAME: TOFACITINIB; REGISTRATION NO/DATE: SWISSMEDIC 62630 12.07.2013
1666481	37/2017	Austria		PRODUCT NAME: TOFACITINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES, EINSCHLIESSLICH DES CITRATS; REGISTRATION NO/DATE: EU/1/17/1178 (MITTEILUNG) 20170324

Market Dynamics and Financial Trajectory for Tofacitinib Citrate

Last updated: April 17, 2026

Tofacitinib citrate, marketed as Xeljanz by Pfizer, is an oral Janus kinase (JAK) inhibitor approved primarily for rheumatoid arthritis (RA), psoriatic arthritis, ulcerative colitis, and other autoimmune conditions. It is a key player in the immunomodulatory drug segment, with expanding indications and competitive pressures shaping its market trajectory.

Market Overview

Approved Indications

• Rheumatoid arthritis (FDA approval: 2012)
• Psoriatic arthritis (2017)
• Ulcerative colitis (2018)
• Other off-label and pipeline uses in autoimmune diseases

Competitive Landscape

• Main competitors: AbbVie’s Skyrizi, Eli Lilly’s Olumiant, Roche’s Actemra
• Patent stability: Expired or close to expiry for certain formulations (e.g., 2027-2028 in the U.S.), increasing generic entry risk
• Biosimilars and generics: Potential to erode market share post-patent expiry

Patient Population

• Globally, millions suffer from rheumatoid arthritis alone; estimates exceeding 20 million based on global disease burden data
• Market penetration remains incomplete, creating space for expanded usage

Regulatory Environment

• U.S.: Approved with two-year safety profile; ongoing post-market surveillance
• Europe and Japan: Approvals follow U.S. decisions, with some regional variations

Sales and Revenue Performance

Historical Sales Data

• 2022 global revenue: Approximately $2.3 billion (Pfizer, FY2022)
• Growth rate (CAGR 2016-2022): ~19%
• Peak sales forecasts: Exceeds $3 billion by 2025 in base case projections

Regional Breakdown

Region	2022 Revenue	Growth (2016-22 CAGR)	Notes
United States	$1.1 billion	20%	Dominates with Rx volume increases
Europe	$660 million	17%	Key market with regional approval compliance
Rest of World	$550 million	15%	Growth driven by emerging markets

Market Drivers

• Increasing adoption in rheumatoid arthritis, especially in biologic-naive patients
• Growing awareness and diagnosis rates
• New formulations and oral convenience appeal

Challenges

• Patent expiration risk, particularly in mature markets
• Cost concerns relative to biosimilars
• Safety profile considerations, especially related to infections and malignancies, impacting prescribing decisions

Financial Trajectory Outlook

Short-term Projections (2023-2025)

• Continued growth in existing indications
• Margin improvements driven by operational efficiencies
• Potential impact from entry of biosimilars or generics post-patent expiry

Long-term Outlook (2026 and beyond)

• Pipeline expansions and new indications could drive sales
• With patent cliff approaching, revenue may decline unless offset by biosimilar market share gains
• Strategic diversification into other autoimmune or inflammatory diseases could stabilize revenues

R&D and Pipeline Investment

• Pfizer investing in combination therapies
• Development of subcutaneous and intravenous formulations
• Trials underway for alopecia areata, atopic dermatitis, and other autoimmune conditions

Market Risks and Opportunities

Risks

• Patent expiry in key markets by late 2020s
• Regulatory hurdles or safety concerns
• Pricing pressure from biosimilars and generics

Opportunities

• Expanding indications, such as alopecia areata (FDA approval expected in 2024)
• Geographic expansion into emerging markets
• Formulation innovations improving patient adherence

Key Takeaways

• Tofacitinib citrate’s revenue is driven by its initial and expanded indications, with sales reaching approximately $2.3 billion in 2022.
• The drug faces patent expiry risks by 2027 in the U.S., with biosimilar competition likely to reduce revenues.
• Pfizer maintains growth through pipeline expansion and geographic penetration, especially in emerging markets.
• Market dynamics are shaped by regulatory developments, safety profiles, and competitive pressures from biologics and biosimilars.
• Long-term financial success hinges on pipeline progress and successful indication expansion.

FAQs

1. When will patent protection for Tofacitinib citrate expire in major markets?
Patent protection in the U.S. is expected to expire around 2027-2028, with Europe and other regions following similar timelines.

2. What are the primary drivers of Tofacitinib’s sales growth?
Increasing adoption across autoimmune indications, global expansion, and improved patient compliance due to oral administration.

3. How significant is biosimilar competition for Tofacitinib?
While biosimilar competition is limited due to Tofacitinib being a small-molecule drug, generic entry post-patent expiry could reduce revenues significantly.

4. What pipeline developments could influence future revenues?
Applications for alopecia areata, atopic dermatitis, and new formulations are under review, potentially expanding the drug’s market.

5. How does safety profile affect Tofacitinib’s market trajectory?
Concerns surrounding infections and malignancies impact clinical use and may motivate safety-related label updates, affecting uptake.

References

1. Pfizer. (2022). Xeljanz (Tofacitinib) prescribing information.
2. FDA. (2012). Approval of Xeljanz for rheumatoid arthritis.
3. IQVIA. (2023). Global Pharma Market Data.
4. EvaluatePharma. (2023). World Predictive Sales Data.
5. European Medicines Agency. (2018). Tofacitinib approval updates.